About Us

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 150 employees.

Our goal is to build an enduring biopharmaceutical company with a foundation of products and product candidates that significantly advance patient care in the areas of thrombosis, other hematologic disorders and inflammation. We are advancing our three compounds using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of our potentially life-saving therapies.

  • Betrixaban –  Betrixaban, which was granted a Fast track designation by the FDA, is a novel oral once-daily inhibitor of FXa in development for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use. Acute medically ill patients are those hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease. Learn More
  • Andexanet alfa – an FDA-designated breakthrough therapy, is a recombinant protein designed to reverse anticoagulant activity in patients treated with a FXa inhibitor. Andexanet alfa has potential indications for patients anticoagulated with a direct or indirect FXa inhibitor when reversal of anticoagulation is needed, such as in life-threatening or uncontrolled bleeding or for emergency surgery or urgent procedures. Currently, there is no antidote or reversal agent approved for use against FXa inhibitors. We have completed Phase 3 registration studies in healthy volunteers and are currently evaluating Andexanet alfa in Phase 2 clinical trials. We are also conducting a Phase 4 confirmatory trial in patients. We filed a Biologics License Application, or BLA, to the FDA in the first quarter of 2016. The BLA is subject to review under an Accelerated Approval pathway with a Prescription Drug User Fee Act, or PDUFA, date of August 17, 2016. The PDUFA date is the goal date for the FDA to complete its review of the BLA. Learn more.
  • Cerdulatinib (PRT2070) –  an oral, dual Syk-JAK inhibitor. We are developing it to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. Cerdulatinib is being developed for hematologic, or blood, cancers and inflammatory disorders. We are currently conducting a Phase 1/2a proof-of-concept study for Cerdulatinib in patients with non-Hodgkin’s lymphoma, or NHL, or chronic lymphocytic leukemia, or CLL, who have failed or relapsed on existing marketed therapies or products in development, including patients with identified mutations. Learn more.